Pancreatic cancer is one of the most lethal diagnoses a person can receive. Five-year survival rates linger in the single digits. Treatment options are limited, often brutal.
Surgery is the gold standard, but many patients are not candidates. Chemotherapy and radiation carry punishing side effects.
Sonire Therapeutics is betting on sound waves instead. The Palo Alto-based company announced this week that its Japanese subsidiary, Sonire Therapeutics KK, has been selected for a grant program run by Japan’s New Energy and Industrial Technology Development Organization (NEDO). The grant comes from NEDO’s Deep-Tech Startups Support Program, or DTSU.
It is non-dilutive funding — meaning Sonire does not give up equity. The money is earmarked for commercializing, developing, and expanding the company’s Ultrasound-Guided HIFU Platform.
HIFU stands for high-intensity focused ultrasound. The technology works like a magnifying glass concentrating sunlight. A transducer sends sound waves through the body, focusing them on a precise point inside a tumor.
The energy heats the tissue to a temperature that kills cancer cells. Surrounding healthy tissue, the company says, is spared. The key innovation Sonire is pushing is combining HIFU with real-time ultrasound imaging.
Standard HIFU systems often rely on MRI for guidance — expensive, slow, and bulky. Ultrasound imaging is cheaper, faster, and portable.
By guiding the treatment with ultrasound, Sonire’s platform allows clinicians to see the target, deliver the energy, and adjust on the fly. That is the core of the company’s strategy. The NEDO grant is not a small sum.
The company disclosed $13 million in funding from the program. That money is meant to push Sonire’s pancreatic cancer treatment toward global commercialization.
Pancreatic tumors are notoriously difficult to treat. They are often deep in the abdomen, wrapped around major blood vessels. Surgery is high-risk.
HIFU offers a non-invasive route. No incisions. No recovery from a scalpel.
Just sound waves passing through the skin. Sonire Therapeutics is a clinical-stage medical device company.
It is U.S.-based but has a group company in Japan. That structure likely helped secure the NEDO grant, which supports Japanese startups. The DTSU program targets deep-tech ventures — companies working on hard science problems, not software apps.
HIFU fits that description. The company has not released a timeline for when the pancreatic cancer treatment might reach patients.
Clinical trials take time. Regulatory approvals take longer. But the funding gives Sonire runway to keep developing the platform and expand its operations.
The real test will be whether the ultrasound guidance actually improves outcomes. HIFU has been studied for decades. It is used for uterine fibroids, prostate cancer, and bone metastases.
But pancreatic cancer remains a stubborn frontier. The organ is mobile.
It shifts with breathing. The tumor can be irregularly shaped. Targeting it precisely with sound waves requires accuracy that older systems struggled to deliver.
Sonire believes its platform solves that problem. The company is betting that real-time imaging will make HIFU reliable enough for routine use against pancreatic cancer.
If it works, it could change the standard of care. If it does not, it will be another promising technology that could not clear the bar. For now, the NEDO grant is a signal.
A government agency with a track record of backing deep-tech startups has put money behind Sonire’s approach. That is not a guarantee of success. But it is a vote of confidence.
And for a company trying to turn sound waves into a weapon against one of the deadliest cancers, confidence — and cash — matter.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Sonire Therapeutics’ Japanese Unit Wins Grant for Ultrasound-Based Cancer Therapy”, “description”: “Pancreatic cancer is one of the most lethal diagnoses a person can receive. Five-year survival rates linger in the single digits. Treatment options are limited,…”, “datePublished”: “2026-06-17T08:30:00+00:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Henry Thomas”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
